Literature DB >> 16033731

Acromegaly as an endocrine form of myopathy: case report and review of literature.

Tammy L McNab1, Hasnain M Khandwala.   

Abstract

OBJECTIVE: To describe a case of muscle weakness in a patient with acromegaly and to review the pathophysiologic features of this disorder.
METHODS: We present the clinical, laboratory, electromyographic, and muscle biopsy findings in our patient and review related reports in the literature.
RESULTS: A 58-year-old woman with acromegaly presented with complaints of bilateral hip pain, weakness, and instability 8 months after transsphenoidal resection of a growth hormone (GH)-secreting pituitary macroadenoma. She had biochemically normal thyroid and adrenal function and no evidence of any neuropathy, inflammatory myopathy, or rheumatologic disorder to explain her symptoms. Investigations revealed increased levels of GH, insulin-like growth factor-I, serum creatine kinase (CK), and the MB fraction of CK, normal results of nerve conduction studies, and nonspecific findings on electromyography and muscle biopsy. A review of the literature revealed that although muscle weakness is a well-recognized feature of acromegaly, only a few cases similar to ours have been reported since acromegaly was first described in the late 1800s. Little is known about the natural history, best diagnostic approach, and optimal therapy for this debilitating complication.
CONCLUSION: Muscle weakness in acromegaly is common and may result from a combination of the direct effect of GH excess on muscle and other metabolic derangements (hypothyroidism, hypoadrenalism, or diabetes). Mechanical factors may also contribute, such as joint laxity in conjunction with hypermobility. Affected patients may benefit from a reduction in GH levels and physiotherapy for adaptive training. Persistently increased serum CK levels in a patient with diabetes, for whom no other cause is found, should prompt an investigation for acromegaly. More research into this aspect of acromegaly is needed for enhancement of our understanding of, and therapy for, this debilitating condition.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033731     DOI: 10.4158/EP.11.1.18

Source DB:  PubMed          Journal:  Endocr Pract        ISSN: 1530-891X            Impact factor:   3.443


  6 in total

1.  The clinical use of macro and surface electromyography in diagnosis and follow-up of endocrine and drug-induced myopathies.

Authors:  M A Minetto; A Rainoldi; J F Jabre
Journal:  J Endocrinol Invest       Date:  2007-10       Impact factor: 4.256

2.  Human growth hormone: a Paul Bunyan drug or a drug for Paul's bunion.

Authors:  George T Griffing
Journal:  MedGenMed       Date:  2007-12-03

Review 3.  Growth hormone, IGF-I and insulin and their abuse in sport.

Authors:  R I G Holt; P H Sönksen
Journal:  Br J Pharmacol       Date:  2008-03-31       Impact factor: 8.739

Review 4.  Detecting growth hormone misuse in athletes.

Authors:  Richard I G Holt
Journal:  Indian J Endocrinol Metab       Date:  2013-10

5.  On the functional capacity and quality of life of patients with acromegaly: are they candidates for rehabilitation programs?

Authors:  Débora Pedroza Guedes da Silva; Fernando Silva Guimarães; Cristina Márcia Dias; Simone de Araujo Guimarães; Leandro Kasuki; Mônica Roberto Gadelha; Gustavo Bittencourt Camilo; Agnaldo José Lopes
Journal:  J Phys Ther Sci       Date:  2013-12-11

6.  Myokines in Acromegaly: An Altered Irisin Profile.

Authors:  Łukasz Mizera; Jowita Halupczok-Żyła; Katarzyna Kolačkov; Agnieszka Zembska; Jędrzej Grzegrzółka; Diana Jędrzejuk; Marek Bolanowski; Jacek Daroszewski
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-02       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.